Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 814

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 6
Chunk 814
---
 may seek additional financing through the sale of equity, government grants, debt financings or other capital sources, including potential future licensing, collaboration or similar arrangements with third parties or other strategic transactions.

Results of Operations

Fiscal Year Ended September 30, 2025 Compared to the Fiscal Year Ended September 30, 2024

Our total operating expenses increased by $0.9 million to $7.9 million for the year ended September 30, 2025 compared to $7.0 million for the prior year.

			●

			The following table summarizes our R&D expenses incurred for the years ended September 30, 2025 and 2024, together with the dollar increase or decrease in those items:

			Fiscal Year End

			Change

			September 30, 2025

			September 30, 2024

			Program-specific external costs:

			EB06

			$
			339,816

			$
			-

			$
			339,816

			EB05

			1,929,023

			1,444,949

			484,074

			Other development and discovery programs

			133,347

			218,391

			(85,044
			)

			Total program-specific costs

			2,402,186

			1,663,340

			738,846

			Unallocated internal costs

			Non-program specific external costs

			1,206

			9,652

			(8,446
			)

			Unallocated internal costs

			1,265,346

			1,208,975

			56,371

			Total unallocated internal costs

			1,266,552

			1,218,627

			47,925

			Total research and development costs

			3,668,738

			2,881,967

			786,771

			●

			Research and development (“R&D”) expenses increased by $0.8 million to $3.7 million for the year ended September 30, 2025 compared to $2.9 million for the prior year primarily due to increased expenses for manufacturing-related activities and other preparations for the planned Phase 2 clinical study of EB06 in vitiligo patients, as well as increased research expenses related to